AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Altimmune Plunges 51.23% on Disappointing Trial Results
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jun 26, 2025 7:13 am ET1min read
On June 26, 2025, Altimmune's stock price plummeted by 51.23% in pre-market trading, marking a significant downturn for the biotech company.
Altimmune's recent stock volatility can be attributed to several key developments. The company announced that it would disclose top-line results from its 24-week Phase 2b IMPACT trial, which initially boosted investor optimism and led to a surge in after-hours trading. However, the subsequent market reaction suggests that the results may not have met investor expectations, leading to the sharp decline in stock price.
Analysts from H.C. Wainwright and Laidlaw & Company have maintained a positive outlook on
, with both firms rating the stock as a Buy. H.C. Wainwright set a price target of $15, while Laidlaw & Company aimed for $16. These ratings indicate confidence in the company's long-term prospects, despite the recent market turbulence.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
SEALSQ Surged 8.29% Driven by 2026–2030 Roadmap for Silicon-Based Quantum Computing Systems
Dec.19 2025
Serve Robotics (SERV) Surges 5.97% on Bullish Oppenheimer Note
Dec.19 2025
AXT Inc. shares surge 13.35% on renewed earnings upside speculation amid supply chain adjustments
Dec.19 2025
PROK surged 5.11% on Dec. 19 2025 after HC Wainwright upgraded to Buy rating
Dec.19 2025
Tesla shares surge 3.45% as SpaceX orders 1,000-2,000 Cybertrucks for Starbase facility.
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet